Compare AQN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQN | ABCL |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.5B |
| IPO Year | 2002 | 2020 |
| Metric | AQN | ABCL |
|---|---|---|
| Price | $5.02 | $12.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $6.66 | ★ $8.40 |
| AVG Volume (30 Days) | ★ 4.0M | 4.0M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $5.02 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $5.00 | $2.75 |
| 52 Week High | $7.11 | $13.18 |
| Indicator | AQN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 23.23 | 59.17 |
| Support Level | N/A | $10.38 |
| Resistance Level | $6.06 | $12.58 |
| Average True Range (ATR) | 0.11 | 0.56 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 0.00 | 62.24 |
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units: the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution, and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.